Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2024.02.08

A scenic view of Sai Life Sciences' Integrated Discovery & Development Campus in Hyderabad, featuring modern research buildings, a lush green landscape, and a serene water body with floating lily pads, symbolizing the company’s commitment to sustainability and eco-friendly operations.

Sai Life Sciences releases its Sustainability Report 2023

Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO/ CDMO), released its Sustainability Report 2022-2023. Developed in accordance with the Global Reporting Initiative (GRI) Universal Standards 2021 framework, the fourth edition of the Sustainability report is based on the theme ‘Steadfast on Sustainability,’ and it articulates the company’s commitment to sustainability and the journey so far. Read the full report here.

Making this announcement, Krishna Kanumuri, CEO & Managing Director, stated, “I am delighted to present our fourth successive Sustainability Report, reflecting our commitment to the sustainability journey and to conduct our business responsibly. In 2023, we reset our Sustainable Development Goals to attain specific Environmental, Social, and Governance (ESG) targets by March 31, 2027. The learnings and insights gleaned from our previous experience have shaped our SDGs for this phase, reflecting confidence in our ability to strive for and achieve more ambitious targets.”

The fourth report released by Sai Life Sciences highlights significant progress in various areas:

Environmental:

  • Joined the Science Based Targets initiative (SBTi), a global body enabling businesses to set ambitious emission reduction targets in line with the latest climate science. Accordingly, the company has committed to set near-term company-wide emission reductions in line with climate science with the SBTi.
  • Joined the Sustainable Markets Initiative (SMI) of Manufacture 2030, fostering collaboration with the company’s pharma partners to implement tangible measures for decarbonizing healthcare supply chains.

Social:

  • Strengthened the company’s commitment to social accountability through the implementation of robust policies addressing labor and human rights. Nurtured an agile workforce by embracing diversity across age and gender at all management levels, with dedicated efforts toward empowering women throughout the organization.

Governance:

  • Established the 'Sustainability Governance Council' to seamlessly integrate sustainability matters into the company’s business strategy and oversee the effective enforcement of the sustainability mandate.

This report underscores the company’s dedication to sustainability and exemplifies the progress made, reinforcing Sai Life Sciences' position as a frontrunner in the pursuit of environmentally conscious and socially responsible business practices.

Share article

More News

2026.03.10

AI-driven retrosynthesis integrated into Discovery Chemistry

Sai Life Sciences has entered into a collaboration with Chemical.AI, a technology company specialising in computer-aided synthesis design, to integrate an AI-driven retrosynthesis platform into its Discovery Chemistry workflows. The integration enables medicinal chemists to evaluate synthetic routes more rapidly and explore a broader set of feasible pathways during early-stage drug discovery. Retrosynthesis is a […]
Read more

2026.03.10

Structural Biology capabilities launched with X-Ray Crystallography

Sai Life Sciences has introduced integrated structural biology capabilities with the establishment of X-ray protein crystallography workflows to support structure-based drug discovery programs. The platform encompasses end-to-end protein engineering capabilities, including construct design, gene synthesis, and in-house recombinant protein expression and purification. These foundational steps enable generation of high-quality protein material suitable for structural and […]
Read more

2026.03.09

New Medicinal Chemistry block set for inauguration in Hyderabad

A new Medicinal Chemistry block, Unit VIII, is set for inauguration at IKP, Genome Valley, Hyderabad, expanding discovery capacity to meet growing program demand. The four-floor facility spans approximately 100,000 sq. ft. and is designed to support large, multi-disciplinary project teams. It accommodates more than 200 fume hoods and includes a tightly integrated analytical laboratory […]
Read more

2026.03.09

AI-enabled production and material planning platform implemented

Over the past several months, focused AI pilot initiatives have been conducted across operations to evaluate practical applications that strengthen execution. One such initiative is now live across the network: Optimus, an integrated AI-enabled production and material planning platform, implemented at the end of December 2025. Optimus consolidates capacity planning, equipment allocation, and material availability […]
Read more

2026.03.09

Commercial-scale Photo Flow Chemistry successfully executed in Bidar

Commercial-scale flow chemistry has been successfully executed at our API manufacturing site in Bidar for a late-phase program supporting a US-based innovator. This execution builds on prior investments in continuous processing infrastructure at the site, including a 3-litre photo flow reactor equipped with a monochromatic blue LED light source. The platform enables controlled photochemical transformations […]
Read more